Julie R. Brahmer, MD | Authors


Clarifying Mechanisms of Resistance May Enhance Treatment Strategies

November 14, 2019

Although immune checkpoint inhibitor therapy has represented a paradigm shift in the treatment of multiple types of cancer, many patients’ cancers do not respond at all to these therapies or develop resistance after an initial period of response, according to Julie R. Brahmer, MD.

Impact of Durvalumab as Consolidation Therapy in NSCLC

June 06, 2018

Julie R. Brahmer, MD, associate professor of oncology and co-director of the Upper Aerodigestive Department at the Bloomberg Kimmel Institute for Cancer Immunotherapy, John Hopkins Medicine, discusses the change in standard of care for patients with stage III non–small cell lung cancer. Durvalumab was recently approved by the FDA as a consolidation therapy for patients with stage III locally-advanced, unresectable NSCLC who had not progressed following standard chemoradiotherapy.

Dr. Brahmer Reviews Lung Cancer Advancements in 2017

December 21, 2017

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, reviews developments in 2017 for the treatment of lung cancer.